This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

A Randomized, Multicenter, Double-blind, Placebo-Controlled Trial

Spotswood L. Spruance, MD; Ted L. Rea, MD; Christopher Thoming, MD; Richard Tucker, MD; Robin Saltzman, MD; Ron Boon

JAMA. 1997;277(17):1374-1379.

Abstract
Objective.
—To compare the safety and efficacy of topical 1% penciclovir cream with vehicle control cream (placebo) for the treatment of a recurrent episode of herpes simplex labialis (cold sores) in immunocompetent patients.

Design.
—Randomized, double-blind, placebo-controlled, patient-initiated, 2-armed, parallel clinical trial. Patients were prospectively dispensed study medication, and treatment was self-initiated by the patient within 1 hour of the first sign or symptom of a recurrence.

Setting.
—A total of 31 ambulatory clinics in the United States in a variety of settings, including private practices, public health facilities, and universities.

Patients.
—Otherwise healthy individuals with a history of frequent episodes of herpes simplex labialis. A total of 2209 patients were enrolled and given study medication, and 1573 initiated treatment for a recurrence.

Interventions.
—Topical 1% penciclovir cream or vehicle control cream. Subjects applied treatment every 2 hours while awake for 4 consecutive days.

Main Outcome Measures.
—Lesion healing was the primary efficacy variable. Secondary end points included time to loss of lesion pain and time to cessation of viral shedding.

Results.
—Healing of classical lesions (vesicles, ulcers, and/or crusts) was 0.7 day faster for penciclovir-treated patients compared with those who received vehicle control cream (median, 4.8 days vs 5.5 days; hazard ratio [HR], 1.33; 95% confidence interval [CI], 1.18-1.49; P<.001). Pain (median, 3.5 days vs 4.1 days; HR, 1.22; 95% CI, 1.09-1.36; P<.001) and lesion virus shedding (median, 3 days vs 3 days; HR, 1.35; 95% CI, 1.10-1.64; P=.003) also resolved more quickly for penciclovir-treated patients compared with patients who applied the vehicle control. The efficacy of penciclovir cream was apparent when therapy was initiated early (prodrome or erythema lesion stage) and when initiated late (papule or vesicle stage). The incidence of adverse events was comparable between penciclovir and placebo groups.

Conclusions.
—Penciclovir cream is the first treatment to clearly demonstrate an impact on the course of recurrent herpes labialis in immunocompetent patients. Efficacy was seen in all clinical and laboratory measures of the disease (lesion healing, pain resolution, and cessation of viral shedding). Faster healing and pain resolution occurred both among patients who first applied penciclovir cream in the prodrome and erythema stages and among those who started treatment in the papule and vesicle lesion stages.

Author Affiliations
for the Topical Penciclovir Collaborative Study Group

From the Division of Infectious Diseases, University of Utah, Salt Lake City (Dr Spruance); VIP Research, Inc, Bryan, Tex (Dr Rea); Westover Heights Clinic, Portland, Ore (Dr Thoming); Wenatchee Valley Clinic, Wenatchee, Wash (Dr Tucker); SmithKline Beecham Pharmaceuticals, Philadelphia, Pa (Dr Saltzman); and SmithKline Beecham Pharmaceuticals, Brentford, Middlesex, London, England (Mr Boon).

Footnotes
A complete list of the members of the Topical Penciclovir Collaborative Study Group appears at the end of this article.

The results of this trial were presented in part at the Clinical Dermatology 2000 International Congress, Vancouver, British Columbia, May 30, 1996.

Reprints: Spotswood L. Spruance, MD, Health Sciences AIDS Center, School of Medicine, University of Utah, 50 N Medical Dr, Room 4B319, Salt Lake City, UT 84132.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Treatment and prevention of herpes labialis
Opstelten et al.
cfp 2008;54:1683-1687.
ABSTRACT | FULL TEXT  

The Treatment of Herpes Simplex Infections: An Evidence-Based Review
Cernik et al.
Arch Intern Med 2008;168:1137-1144.
ABSTRACT | FULL TEXT  

Treating Patients with Herpes Simplex Virus Infections: Dental and Dental Hygiene Students' Knowledge, Attitudes, and Professional Behavior
Kanjirath et al.
J Dent Educ 2007;71:1133-1144.
ABSTRACT | FULL TEXT  

Statistical Significance and Clinical Relevance: The Importance of Power in Clinical Trials in Dermatology
Bhardwaj et al.
Arch Dermatol 2004;140:1520-1523.
ABSTRACT | FULL TEXT  

Oral Antivirals for the Acute Treatment of Recurrent Herpes Labialis
Jensen et al.
The Annals of Pharmacotherapy 2004;38:705-709.
ABSTRACT | FULL TEXT  

A Review of Common Pediatric Lip Lesions: Herpes Simplex/Recurrent Herpes Labialis, Impetigo, Mucoceles, and Hemangiomas
Bentley et al.
CLIN PEDIATR 2003;42:475-482.
ABSTRACT  

High-Dose, Short-Duration, Early Valacyclovir Therapy for Episodic Treatment of Cold Sores: Results of Two Randomized, Placebo-Controlled, Multicenter Studies
Spruance et al.
Antimicrob. Agents Chemother. 2003;47:1072-1080.
ABSTRACT | FULL TEXT  

Herpes Simplex Virus Resistance to Acyclovir and Penciclovir after Two Decades of Antiviral Therapy
Bacon et al.
Clin. Microbiol. Rev. 2003;16:114-128.
ABSTRACT | FULL TEXT  

Penciclovir Susceptibilities of Herpes Simplex Virus Isolates from Patients Using Penciclovir Cream for Treatment of Recurrent Herpes Labialis
Sarisky et al.
Antimicrob. Agents Chemother. 2002;46:2848-2853.
ABSTRACT | FULL TEXT  

Surveillance for Antiviral-Agent-Resistant Herpes Simplex Virus in the General Population with Recurrent Herpes Labialis
Bacon et al.
Antimicrob. Agents Chemother. 2002;46:3042-3044.
ABSTRACT | FULL TEXT  

Diagnosis and management of recurrent herpes simplex infections
SIEGEL
Journal of the American Dental Association 2002;133:1245-1249.
ABSTRACT | FULL TEXT  

Acyclovir Cream for Treatment of Herpes Simplex Labialis: Results of Two Randomized, Double-Blind, Vehicle-Controlled, Multicenter Clinical Trials
Spruance et al.
Antimicrob. Agents Chemother. 2002;46:2238-2243.
ABSTRACT | FULL TEXT  

Double-Blind, Randomized, Placebo-Controlled Study of Topical 5% Acyclovir-1% Hydrocortisone Cream (ME-609) for Treatment of UV Radiation-Induced Herpes Labialis
Evans et al.
Antimicrob. Agents Chemother. 2002;46:1870-1874.
ABSTRACT | FULL TEXT  

Effective treatment of herpes simplex labialis with penciclovir cream: Combined results of two trials
RABORN et al.
Journal of the American Dental Association 2002;133:303-309.
ABSTRACT | FULL TEXT  

Comparison of New Topical Treatments for Herpes Labialis: Efficacy of Penciclovir Cream, Acyclovir Cream, and n-Docosanol Cream Against Experimental Cutaneous Herpes Simplex Virus Type 1 Infection
McKeough and Spruance
Arch Dermatol 2001;137:1153-1158.
ABSTRACT | FULL TEXT  

A Review of Antiviral Therapy for Herpes Labialis
Vander Straten et al.
Arch Dermatol 2001;137:1232-1235.
FULL TEXT  

Effects of Antiviral Usage on Transmission Dynamics of Herpes Simplex Virus Type 1 and on Antiviral Resistance: Predictions of Mathematical Models
Lipsitch et al.
Antimicrob. Agents Chemother. 2000;44:2824-2835.
ABSTRACT | FULL TEXT  

Efficacies of Topical Formulations of Foscarnet and Acyclovir and of 5-Percent Acyclovir Ointment (Zovirax) in a Murine Model of Cutaneous Herpes Simplex Virus Type 1 Infection
Piret et al.
Antimicrob. Agents Chemother. 2000;44:30-38.
ABSTRACT | FULL TEXT  

What is meant by intention to treat analysis? Survey of published randomised controlled trials
Hollis and Campbell
BMJ 1999;319:670-674.
ABSTRACT | FULL TEXT  

Intravenous Penciclovir for Treatment of Herpes Simplex Infections in Immunocompromised Patients: Results of a Multicenter, Acyclovir-Controlled Trial
Lazarus et al.
Antimicrob. Agents Chemother. 1999;43:1192-1197.
ABSTRACT | FULL TEXT  

Antiviral Drugs
Balfour
NEJM 1999;340:1255-1268.
FULL TEXT  

Discussion Sections in Reports of Controlled Trials Published in General Medical Journals: Islands in Search of Continents?
Clarke and Chalmers
JAMA 1998;280:280-282.
ABSTRACT | FULL TEXT  

Contempo 1997: Dermatology
Marks and Saltzman
JAMA 1997;278:1148-1148.
ABSTRACT  

Penciclovir Cream Disappointing in Recurrent Herpes Labialis
Journal Watch Dermatology 1997;1997:12-12.
FULL TEXT  

Penciclovir Speeds Cold Sore Healing
Journal Watch Dermatology 1997;1997:14-14.
FULL TEXT  

PENCICLOVIR SPEEDS COLD SORE HEALING
JWatch General 1997;1997:4-4.
FULL TEXT